Starpharma Holdings Ltd
ASX:SPL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Starpharma Holdings Ltd
ASX:SPL
|
AU |
|
AIMA Technology Group Co Ltd
SSE:603529
|
CN |
|
AST SpaceMobile Inc
NASDAQ:ASTS
|
US |
|
M
|
Molibdenos y Metales SA
SGO:MOLYMET
|
CL |
|
Kamaz PAO
MOEX:KMAZ
|
RU |
|
Novogene Co Ltd
SSE:688315
|
CN |
|
Gozde Girisim Sermayesi Yatirim Ortakligi AS
IST:GOZDE.E
|
TR |
|
Borqs Technologies Inc
OTC:BRQSF
|
CN |
|
G
|
Golden Heaven Group Holdings Ltd
NASDAQ:GDHG
|
CN |
|
E
|
Econach Holdings Co Ltd
TSE:3521
|
JP |
|
Is Finansal Kiralama AS
IST:ISFIN.E
|
TR |
|
J
|
Joongang DNM Co Ltd
KOSDAQ:051980
|
KR |
|
People's Insurance Company Group of China Ltd
OTC:PINXF
|
CN |
|
Honkarakenne Oyj
LSE:0EPR
|
FI |
|
Eli Lilly and Co
NYSE:LLY
|
US |
|
BNR Udyog Ltd
BSE:530809
|
IN |
|
Y
|
YIT Oyj
OMXH:YIT
|
FI |
|
Cambridge Nutritional Sciences PLC
LSE:CNSL
|
UK |
|
Suzhou TZTEK Technology Co Ltd
SSE:688003
|
CN |
|
Strawbear Entertainment Group
HKEX:2125
|
CN |
Starpharma Holdings Ltd
Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. The company is headquartered in Melbourne, Victoria and currently employs 50 full-time employees. The company went IPO on 2000-09-28. The firm is engaged in development of dendrimer products for pharmaceutical, life science and other applications. The firm has two core development programs: VivaGel portfolio and Dendrimer Enhanced Product (DEP) drug delivery. VivaGel BV for bacterial vaginosis (BV) is a women’s health product. The company is available for sale under the brand names, Betafem BV Gel (UK), Betadine BV (Europe), Betadine BV Gel (Asia) and Fleurstat BVgel (Australia and New Zealand). DEP is a drug delivery platform, which provides demonstrated reproducible preclinical benefits across various internal and partnered DEP programs, including improved efficacy, safety, and survival. The firm has three internal DEP products includes DEP docetaxel, DEP cabazitaxel and DEP irinotecan. These internal DEP Products are in clinical development. The firm develops several products internally and others via commercial partnerships.
Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. The company is headquartered in Melbourne, Victoria and currently employs 50 full-time employees. The company went IPO on 2000-09-28. The firm is engaged in development of dendrimer products for pharmaceutical, life science and other applications. The firm has two core development programs: VivaGel portfolio and Dendrimer Enhanced Product (DEP) drug delivery. VivaGel BV for bacterial vaginosis (BV) is a women’s health product. The company is available for sale under the brand names, Betafem BV Gel (UK), Betadine BV (Europe), Betadine BV Gel (Asia) and Fleurstat BVgel (Australia and New Zealand). DEP is a drug delivery platform, which provides demonstrated reproducible preclinical benefits across various internal and partnered DEP programs, including improved efficacy, safety, and survival. The firm has three internal DEP products includes DEP docetaxel, DEP cabazitaxel and DEP irinotecan. These internal DEP Products are in clinical development. The firm develops several products internally and others via commercial partnerships.
